210 related articles for article (PubMed ID: 32386414)
1. HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood-tumor barrier penetration unlinked to a passive marker.
Gril B; Wei D; Zimmer AS; Robinson C; Khan I; Difilippantonio S; Overstreet MG; Steeg PS
Neuro Oncol; 2020 Nov; 22(11):1625-1636. PubMed ID: 32386414
[TBL] [Abstract][Full Text] [Related]
2. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
Gril B; Palmieri D; Bronder JL; Herring JM; Vega-Valle E; Feigenbaum L; Liewehr DJ; Steinberg SM; Merino MJ; Rubin SD; Steeg PS
J Natl Cancer Inst; 2008 Aug; 100(15):1092-103. PubMed ID: 18664652
[TBL] [Abstract][Full Text] [Related]
3. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
Pourjamal N; Yazdi N; Halme A; Joncour VL; Laakkonen P; Saharinen P; Joensuu H; Barok M
Clin Exp Metastasis; 2024 Apr; 41(2):91-102. PubMed ID: 38367127
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology].
Liang XJ; Gong LY; Zhou F; Zhou DM; Zhu JJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 51(5):797-804. PubMed ID: 31624380
[TBL] [Abstract][Full Text] [Related]
5. Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.
Nounou MI; Adkins CE; Rubinchik E; Terrell-Hall TB; Afroz M; Vitalis T; Gabathuler R; Tian MM; Lockman PR
Pharm Res; 2016 Dec; 33(12):2930-2942. PubMed ID: 27528392
[TBL] [Abstract][Full Text] [Related]
6. Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.
Lyle LT; Lockman PR; Adkins CE; Mohammad AS; Sechrest E; Hua E; Palmieri D; Liewehr DJ; Steinberg SM; Kloc W; Izycka-Swieszewska E; Duchnowska R; Nayyar N; Brastianos PK; Steeg PS; Gril B
Clin Cancer Res; 2016 Nov; 22(21):5287-5299. PubMed ID: 27245829
[TBL] [Abstract][Full Text] [Related]
7. Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer.
Adkins CE; Mohammad AS; Terrell-Hall TB; Dolan EL; Shah N; Sechrest E; Griffith J; Lockman PR
Clin Exp Metastasis; 2016 Apr; 33(4):373-83. PubMed ID: 26944053
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
Lockman PR; Mittapalli RK; Taskar KS; Rudraraju V; Gril B; Bohn KA; Adkins CE; Roberts A; Thorsheim HR; Gaasch JA; Huang S; Palmieri D; Steeg PS; Smith QR
Clin Cancer Res; 2010 Dec; 16(23):5664-78. PubMed ID: 20829328
[TBL] [Abstract][Full Text] [Related]
9. A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.
Le Joncour V; Martins A; Puhka M; Isola J; Salmikangas M; Laakkonen P; Joensuu H; Barok M
Mol Cancer Ther; 2019 Oct; 18(10):1721-1730. PubMed ID: 31292166
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.
Askoxylakis V; Ferraro GB; Kodack DP; Badeaux M; Shankaraiah RC; Seano G; Kloepper J; Vardam T; Martin JD; Naxerova K; Bezwada D; Qi X; Selig MK; Brachtel E; Duda DG; Huang P; Fukumura D; Engelman JA; Jain RK
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26547932
[TBL] [Abstract][Full Text] [Related]
11. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
13. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
McKnight BN; Viola-Villegas NT
Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
[TBL] [Abstract][Full Text] [Related]
14. Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases.
Kanojia D; Balyasnikova IV; Morshed RA; Frank RT; Yu D; Zhang L; Spencer DA; Kim JW; Han Y; Yu D; Ahmed AU; Aboody KS; Lesniak MS
Stem Cells; 2015 Oct; 33(10):2985-94. PubMed ID: 26260958
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.
Gril B; Palmieri D; Qian Y; Smart D; Ileva L; Liewehr DJ; Steinberg SM; Steeg PS
Clin Cancer Res; 2011 Jan; 17(1):142-53. PubMed ID: 21081656
[TBL] [Abstract][Full Text] [Related]
16. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Kodack DP; Chung E; Yamashita H; Incio J; Duyverman AM; Song Y; Farrar CT; Huang Y; Ager E; Kamoun W; Goel S; Snuderl M; Lussiez A; Hiddingh L; Mahmood S; Tannous BA; Eichler AF; Fukumura D; Engelman JA; Jain RK
Proc Natl Acad Sci U S A; 2012 Nov; 109(45):E3119-27. PubMed ID: 23071298
[TBL] [Abstract][Full Text] [Related]
17. An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers.
Shin SH; Park YH; Park SS; Ju EJ; Park J; Ko EJ; Bae DJ; Kim SY; Chung CW; Song HY; Jang SJ; Jeong SY; Song SY; Choi EK
Adv Sci (Weinh); 2021 Dec; 8(23):e2102414. PubMed ID: 34664433
[TBL] [Abstract][Full Text] [Related]
18. Brain Metastasis from HER2-Positive Breast Cancer: An Evolving Landscape.
Soffietti R; Pellerino A
Clin Cancer Res; 2023 Jan; 29(1):8-10. PubMed ID: 36305867
[TBL] [Abstract][Full Text] [Related]
19. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
Wang W; He H; Marín-Ramos NI; Zeng S; Swenson SD; Cho HY; Fu J; Beringer PM; Neman J; Chen L; Schönthal AH; Chen TC
Neuro Oncol; 2021 Oct; 23(10):1656-1667. PubMed ID: 33659980
[TBL] [Abstract][Full Text] [Related]
20. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
